15:50 GMT26 January 2020
Listen Live
    Get short URL

    The new drug is intended to help adult patients with newly diagnosed acute myeloid leukemia.

    WASHINGTON (Sputnik) — The US Food and Drug Administration has approved a new drug called Rydapt to treat cancer patients with newly diagnosed acute myeloid leukemia, the administration announced in a press release on Friday.

    "The US Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy," the release stated.

    Rydapt is a kinase inhibitor that blocks several enzymes that promote cell growth.

    The FDA said the drug is approved for use in combination with the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.

    AML is a rapidly progressing cancer that forms in the bone marrow which leads to an increased number of white blood cells in the bloodstream.

    The National Cancer Institute estimated approximately 19,930 people were diagnosed with AML in 2016, and 10,430 were projected to die of the disease.


    Google's Artificial Intelligence Detects Cancer Faster Than Doctors
    Study Shows Nanoparticles Can Boost Cancer Drug Efficiency
    Breakthrough: Experimental New Treatment Kills Cancer Cells, Skips Healthy Ones
    Hope for Millions: Russian Scientists Invent Nanoparticles That Kill Cancer
    acute myeloid leukemia, cancer, Rydapt, Food and Drug Administration, United States
    Community standardsDiscussion
    Comment via FacebookComment via Sputnik